Concourse Financial Group Securities, Inc. Onconova Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

14 transactions

Quarter	Operation	Price Per share
Q2 2024 Jul 23, 2024	BUY	$0.57 - $1.0 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$0.67 - $1.01 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$0.62 - $0.79 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$0.71 - $1.15 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$0.71 - $1.15 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$0.67 - $1.42 $0 - $0
Q1 2023 May 15, 2023	BUY	$0.69 - $1.42 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$0.63 - $0.97 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$0.95 - $1.45 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.04 - $1.9 $0 - $0
Q1 2022 May 09, 2022	BUY	$1.46 - $2.82 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$2.49 - $3.73 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$3.81 - $6.76 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$6.28 - $16.2 $0 - $0

Others Institutions Holding ONTX

# of Institutions

Shares Held

249K

Call Options Held

Put Options Held

View Full List

About Onconova Therapeutics, Inc.

Ticker ONTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,895,600
Market Cap $12.3M
Description
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...

More about ONTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account